GLP-1 Price Tracker: May 2026 Update
Price verification — October 26, 2026
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
- Wegovy (semaglutide): Wegovy tablet: $149/30 tablets at 1.5 mg, $199 at 4 mg (a temporary $149 4 mg offer may apply), and $299 at 9 mg or 25 mg. Wegovy injection: eligible new patients may pay $199 per 28-day fill for the first two fills at 0.25 or 0.5 mg through Dec. 31, 2026, then generally $349 for standard pen doses. Eligibility and dosage restrictions apply. Official source
- Zepbound (tirzepatide): LillyDirect self-pay: 2.5 mg starts at $299/28 days, 5 mg at $399, and 7.5 mg and above at $449 only with qualifying 45-day refill timing. Higher-dose prices can be higher when those conditions are not met. Supplies may cost extra. Official source
- Clinical program fees: Ivím lists a $74.99/month membership with medication billed separately. Sesame lists care from $59/month on a 12-month commitment; month-to-month costs more, and medication is separate. These are care fees, not all-inclusive drug prices. Official source
- Sesame annual-commitment terms: Official source.
These are manufacturer self-pay or listed care-fee examples, not one all-inclusive price or guaranteed prescription. Insurers, clinical visits, pharmacy choice, dosage, supplies, refill conditions and geography can change the amount due. Compounded GLP-1 products are not FDA-approved. Their availability, lawful compounding circumstances and product claims require separate verification. FDA policy.
Prices verified May 22, 2026 · Updated for 2026
May 2026 headline: Foundayo (orforglipron) launched at $149/mo, Novo Nordisk confirmed Wegovy list price cut to $675 starting Jan 2027, and the Medicare GLP-1 Bridge launches July 1 at $50/mo copay. Compounded pricing remains stable at $99–$299/mo. The gap between brand-name and compounded is narrowing faster than expected.
What changed this month
Foundayo launch reshapes oral pricing
Eli Lilly's Foundayo (orforglipron) launched in April 2026 at $149/month through LillyDirect—matching the Wegovy pill's introductory pricing. This is the first oral GLP-1 with no fasting restrictions, making it the most convenient daily option. At ~11% average weight loss, it trades some efficacy for ease of use.
Novo Nordisk's 2027 price cut confirmed
Novo Nordisk announced in February that Wegovy's list price will drop to $675/month starting January 1, 2027—roughly a 50% reduction from the current ~$1,349 list price. This won't affect most patients immediately (manufacturer programs and insurance already reduce the actual cost), but it signals a directional shift that could eventually lower compounded pricing pressure as well.
Medicare GLP-1 Bridge: 5 weeks out
The Medicare GLP-1 Bridge launches July 1, 2026, covering Wegovy, Zepbound, and Foundayo at a $50/month copay for eligible Medicare Part D beneficiaries. Eligibility: BMI ≥35, or BMI ≥27 with qualifying conditions. The Bridge runs through December 31, 2027 (extended from the original December 2026 end date). The BALANCE Model for Medicare Part D was cancelled on April 21, 2026.
Current verified pricing (May 2026)
| Medication/Provider | Type | Monthly cost | Change vs. April |
|---|---|---|---|
| GobyMeds semaglutide | Compounded | From $99 | No change |
| Oak Weight Loss | Compounded | $130 (flat rate) | No change |
| Yucca Health semaglutide | Compounded | From $146 (6-mo) | No change |
| Embody semaglutide | Compounded | $149 first / $299 | No change |
| Foundayo | Brand oral | $149 | NEW |
| Wegovy pill | Brand oral | $149–$299 | No change |
| Zepbound KwikPen | Brand injectable | $299–$699 | No change |
| Wegovy injection | Brand injectable | $349 (NovoCare) | No change |
| Medicare (July 2026) | Brand via Part D | $50 copay | UPCOMING |
Market trends
- Brand-compounded price convergence: With Foundayo at $149/mo and Wegovy pill at $149–$299/mo, the cheapest brand-name oral options now overlap with mid-tier compounded injectable pricing. This erodes compounding's primary advantage (price) while brand-name offers the regulatory certainty compounded can't.
- FDA enforcement continues: 30+ warning letters to GLP-1 telehealth companies in early 2026. Major compounding lab closures (ProRx, BPI Labs). The regulatory environment is tightening.
- Insurance expansion: Beyond Medicare, several major commercial insurers expanded GLP-1 coverage in 2026. Cigna launched a $200/mo Wegovy/Zepbound benefit. UnitedHealthcare expanded formulary access. Check your specific plan—coverage is changing faster than guides can track.
What to watch in June 2026
- Medicare GLP-1 Bridge launch (July 1) — will demand overwhelm supply?
- CagriSema FDA decision timeline update
- FDA compounding enforcement public comment period (closes June 29)
- Potential additional manufacturer cash-pay program adjustments ahead of Medicare launch
🏥 Compare Current Pricing
Compounded medications are not FDA-approved. Consult a licensed provider to determine if treatment is appropriate for you.
GobyMeds
LegitScript-verified. Semaglutide & tirzepatide bundles, free consult, free shipping.
Get StartedEmbody
Compounded semaglutide with metabolic report, 1:1 guidance, and personalized plan.
Oak Weight Loss
Compounded semaglutide and tirzepatide at a single flat rate regardless of dose.
See PlansSesame Care
Access to FDA-approved brand-name GLP-1 medications through licensed providers.
Get StartedSources & References
- Provider pricing verified May 2026.
- CMS: Medicare GLP-1 Bridge design memo, March 2026.
- Novo Nordisk: Wegovy price reduction announcement, Feb 2026.
- Eli Lilly: Foundayo launch pricing, April 2026.
- KFF: "What Medicare's Temporary Program Covering GLP-1s Means for Beneficiaries." March 2026.